Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.

Gallagher SJ, Gunatilake D, Beaumont KA, Sharp DM, Tiffen JC, Heinemann A, Weninger W, Haass NK, Wilmott JS, Madore J, Ferguson PM, Rizos H, Hersey P.

Int J Cancer. 2017 Dec 6. doi: 10.1002/ijc.31199. [Epub ahead of print]

PMID:
29210065
2.

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.

Gide TN, Wilmott JS, Scolyer RA, Long GV.

Clin Cancer Res. 2017 Nov 10. doi: 10.1158/1078-0432.CCR-17-2267. [Epub ahead of print] Review.

PMID:
29127120
3.

Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node Metastases.

Holtkamp LHJ, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, Scolyer RA.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):660. doi: 10.1245/s10434-017-6170-2. Epub 2017 Oct 27. No abstract available.

PMID:
29079922
4.

Skp2-Mediated Stabilization of MTH1 Promotes Survival of Melanoma Cells upon Oxidative Stress.

Wang JY, Liu GZ, Wilmott JS, La T, Feng YC, Yari H, Yan XG, Thorne RF, Scolyer RA, Zhang XD, Jin L.

Cancer Res. 2017 Nov 15;77(22):6226-6239. doi: 10.1158/0008-5472.CAN-17-1965. Epub 2017 Sep 25.

PMID:
28947420
5.

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.

Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA.

Mod Pathol. 2017 Dec;30(12):1666-1676. doi: 10.1038/modpathol.2017.89. Epub 2017 Aug 4.

PMID:
28776578
6.

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.

Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, Kefford RF, Howle JR, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, Rizos H.

Clin Cancer Res. 2017 Oct 15;23(20):6054-6061. doi: 10.1158/1078-0432.CCR-16-1688. Epub 2017 Jul 19.

PMID:
28724663
7.

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, Liniker E, Kong BY, Cooper AJ, Howle JR, Saw RPM, Jakrot V, Lo S, Thompson JF, Carlino MS, Kefford RF, Long GV, Scolyer RA.

Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16.

PMID:
28512174
8.

The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1.

Wilmott JS, Rizos H, Scolyer RA, Long GV.

Clin Cancer Res. 2017 Jun 15;23(12):2921-2923. doi: 10.1158/1078-0432.CCR-17-0669. Epub 2017 May 3.

PMID:
28468948
9.

Whole-genome landscapes of major melanoma subtypes.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ.

Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3.

PMID:
28467829
10.

Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.

Rawson RV, Johansson PA, Hayward NK, Waddell N, Patch AM, Lo S, Pearson JV, Thompson JF, Mann GJ, Scolyer RA, Wilmott JS.

Lab Invest. 2017 Feb;97(2):130-145. doi: 10.1038/labinvest.2016.143. Epub 2017 Jan 9.

11.

Mutation load in melanoma is affected by MC1R genotype.

Johansson PA, Pritchard AL, Patch AM, Wilmott JS, Pearson JV, Waddell N, Scolyer RA, Mann GJ, Hayward NK.

Pigment Cell Melanoma Res. 2017 Mar;30(2):255-258. doi: 10.1111/pcmr.12571. Epub 2017 Mar 7.

PMID:
28024115
12.

The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.

van Kempen LC, Redpath M, Elchebly M, Klein KO, Papadakis AI, Wilmott JS, Scolyer RA, Edqvist PH, Pontén F, Schadendorf D, van Rijk AF, Michiels S, Dumay A, Helbling-Leclerc A, Dessen P, Wouters J, Stass M, Greenwood CM, Ghanem GE, van den Oord J, Feunteun J, Spatz A.

Sci Transl Med. 2016 Dec 14;8(369):369ra177.

PMID:
27974665
13.

Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation.

Fox C, Lambie D, Wilmott JS, Pinder A, Pavey S, Lê Cao KA, Akalin T, Karaarslan IK, Ozdemir F, Scolyer RA, Yamada M, Soyer HP, Schaider H, Gabrielli B.

Pigment Cell Melanoma Res. 2016 Jul;29(4):444-52. doi: 10.1111/pcmr.12489.

PMID:
27166757
14.

BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.

Kakavand H, Walker E, Lum T, Wilmott JS, Selinger CI, Smith E, Saw RP, Yu B, Cooper WA, Long GV, O'Toole SA, Scolyer RA.

Histopathology. 2016 Oct;69(4):680-6. doi: 10.1111/his.12992. Epub 2016 Jun 15.

PMID:
27151331
15.

Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.

De Paoli-Iseppi R, Johansson PA, Menzies AM, Dias KR, Pupo GM, Kakavand H, Wilmott JS, Mann GJ, Hayward NK, Dinger ME, Long GV, Scolyer RA.

Pathology. 2016 Apr;48(3):261-6. doi: 10.1016/j.pathol.2016.01.001. Epub 2016 Mar 9.

PMID:
27020503
16.

Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.

Kakavand H, Wilmott JS, Long GV, Scolyer RA.

Pathology. 2016 Feb;48(2):194-202. doi: 10.1016/j.pathol.2015.12.010. Epub 2016 Jan 20. Review.

PMID:
27020392
17.

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.

Madore J, Strbenac D, Vilain R, Menzies AM, Yang JY, Thompson JF, Long GV, Mann GJ, Scolyer RA, Wilmott JS.

Clin Cancer Res. 2016 Aug 1;22(15):3915-23. doi: 10.1158/1078-0432.CCR-15-1714. Epub 2016 Mar 9.

18.

Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.

Bosisio FM, Wilmott JS, Volders N, Mercier M, Wouters J, Stas M, Blokx WA, Massi D, Thompson JF, Scolyer RA, van Baren N, van den Oord JJ.

Mod Pathol. 2016 Apr;29(4):347-58. doi: 10.1038/modpathol.2016.28. Epub 2016 Feb 12.

19.

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.

Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, Mann GJ, Thompson JF, Cullinane C, Johnston M, Shackleton M, Sandhu S, Bowtell DD, Johnstone RW, Fox SB, McArthur GA, Papenfuss AT, Scolyer RA, Gill AJ, Hicks RJ, Tothill RW.

Cancer Res. 2015 Dec 15;75(24):5228-34. doi: 10.1158/0008-5472.CAN-15-1877. Epub 2015 Dec 1.

20.

Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.

Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D, Kennedy CW, Gluch L, Carmalt H, Mak C, Warrier S, Gee HE, Chan C, McLean A, Walker E, McNeil CM, Beith JM, Swarbrick A, Scolyer RA, O'Toole SA.

Histopathology. 2016 Jul;69(1):25-34. doi: 10.1111/his.12904. Epub 2016 Jan 13.

PMID:
26588661
21.

INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas.

Chi MN, Guo ST, Wilmott JS, Guo XY, Yan XG, Wang CY, Liu XY, Jin L, Tseng HY, Liu T, Croft A, Hondermarck H, Scolyer RA, Jiang CC, Zhang XD.

Oncotarget. 2015 Nov 24;6(37):39891-907. doi: 10.18632/oncotarget.5359.

22.

Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.

Wilmott JS, Field MA, Johansson PA, Kakavand H, Shang P, De Paoli-Iseppi R, Vilain RE, Pupo GM, Tembe V, Jakrot V, Shang CA, Cebon J, Shackleton M, Fitzgerald A, Thompson JF, Hayward NK, Mann GJ, Scolyer RA.

Pathology. 2015 Dec;47(7):683-93. doi: 10.1097/PAT.0000000000000324. Erratum in: Pathology. 2016 Jan;48(1):104.

PMID:
26517638
23.

Recurrent inactivating RASA2 mutations in melanoma.

Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A, Wilmott JS, Gartner JJ, Di Pizio A, Winograd-Katz S, Sindiri S, Rotkopf R, Dutton-Regester K, Johansson P, Pritchard AL, Waddell N, Hill VK, Lin JC, Hevroni Y, Rosenberg SA, Khan J, Ben-Dor S, Niv MY, Ulitsky I, Mann GJ, Scolyer RA, Hayward NK, Samuels Y.

Nat Genet. 2015 Dec;47(12):1408-10. doi: 10.1038/ng.3427. Epub 2015 Oct 26.

24.

Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.

Kakavand H, Vilain RE, Wilmott JS, Burke H, Yearley JH, Thompson JF, Hersey P, Long GV, Scolyer RA.

Mod Pathol. 2015 Dec;28(12):1535-44. doi: 10.1038/modpathol.2015.110. Epub 2015 Sep 25.

25.

Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.

Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, Butler T, Thompson JF, Mann GJ, Haydu LE, Saw RP, Busam KJ, Lo RS, Collisson EA, Hur JS, Spellman PT, Cleaver JE, Gray JW, Huh N, Murali R, Scolyer RA, Bastian BC, Cho RJ.

Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000. doi: 10.1073/pnas.1508074112. Epub 2015 Aug 18.

26.

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.

Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MM, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV.

Cancer. 2015 Nov 1;121(21):3826-35. doi: 10.1002/cncr.29586. Epub 2015 Jul 28.

27.

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling.

Heinemann A, Cullinane C, De Paoli-Iseppi R, Wilmott JS, Gunatilake D, Madore J, Strbenac D, Yang JY, Gowrishankar K, Tiffen JC, Prinjha RK, Smithers N, McArthur GA, Hersey P, Gallagher SJ.

Oncotarget. 2015 Aug 28;6(25):21507-21.

28.

Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications.

Kiyohara E, Donovan N, Takeshima L, Huang S, Wilmott JS, Scolyer RA, Jones P, Somers EB, O'Shannessy DJ, Hoon DS.

Cancer Microenviron. 2015 Aug;8(2):111-8. doi: 10.1007/s12307-015-0168-8. Epub 2015 Jun 18.

29.

Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (<0.1 mm) sentinel lymph node metastases.

Holtkamp LH, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, Scolyer RA.

Ann Surg Oncol. 2015 Sep;22(9):2972-7. doi: 10.1245/s10434-015-4615-z. Epub 2015 May 20.

PMID:
25990968
30.

Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.

Wilmott JS, Colebatch AJ, Kakavand H, Shang P, Carlino MS, Thompson JF, Long GV, Scolyer RA, Hersey P.

Mod Pathol. 2015 Jul;28(7):884-94. doi: 10.1038/modpathol.2015.34. Epub 2015 Apr 3.

31.

RIP1 Kinase Is an Oncogenic Driver in Melanoma.

Liu XY, Lai F, Yan XG, Jiang CC, Guo ST, Wang CY, Croft A, Tseng HY, Wilmott JS, Scolyer RA, Jin L, Zhang XD.

Cancer Res. 2015 Apr 15;75(8):1736-48. doi: 10.1158/0008-5472.CAN-14-2199. Epub 2015 Feb 27.

32.

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, Scolyer RA.

Clin Cancer Res. 2015 Jul 15;21(14):3140-8. doi: 10.1158/1078-0432.CCR-14-2023. Epub 2015 Jan 21.

33.

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.

Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, Long GV, Hersey P, Scolyer RA.

Pigment Cell Melanoma Res. 2015 May;28(3):245-53. doi: 10.1111/pcmr.12340. Epub 2014 Dec 22.

PMID:
25477049
34.

Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells.

Liu YL, Lai F, Wilmott JS, Yan XG, Liu XY, Luan Q, Guo ST, Jiang CC, Tseng HY, Scolyer RA, Jin L, Zhang XD.

Oncotarget. 2014 Nov 30;5(22):11237-51.

35.

TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells.

Sutton SK, Koach J, Tan O, Liu B, Carter DR, Wilmott JS, Yosufi B, Haydu LE, Mann GJ, Thompson JF, Long GV, Liu T, McArthur G, Zhang XD, Scolyer RA, Cheung BB, Marshall GM.

Oncotarget. 2014 Oct 30;5(20):10127-39.

36.

DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations.

Marzese DM, Scolyer RA, Roqué M, Vargas-Roig LM, Huynh JL, Wilmott JS, Murali R, Buckland ME, Barkhoudarian G, Thompson JF, Morton DL, Kelly DF, Hoon DS.

Neuro Oncol. 2014 Nov;16(11):1499-509. doi: 10.1093/neuonc/nou107. Epub 2014 Jun 26.

37.

A light shines on melanoma metastagenesis.

Vilain R, Wilmott JS, Scolyer RA.

Pigment Cell Melanoma Res. 2014 Sep;27(5):696-7. doi: 10.1111/pcmr.12270. Epub 2014 Jun 19. No abstract available.

PMID:
24890897
38.

Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.

Kakavand H, Crainic O, Lum T, O'Toole SA, Kefford RF, Thompson JF, Wilmott JS, Long GV, Scolyer RA.

Pathology. 2014 Apr;46(3):193-8. doi: 10.1097/PAT.0000000000000077.

PMID:
24614711
39.

Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment.

Wilmott JS, Haydu LE, Menzies AM, Lum T, Hyman J, Thompson JF, Hersey P, Kefford RF, Scolyer RA, Long GV.

J Immunol. 2014 Mar 1;192(5):2505-13. doi: 10.4049/jimmunol.1302616. Epub 2014 Jan 31.

40.

Intra-patient heterogeneity of BRAF mutation status: fact or fiction?

Menzies AM, Wilmott JS, Long GV, Scolyer RA.

Br J Cancer. 2014 Oct 14;111(8):1678-9. doi: 10.1038/bjc.2013.796. Epub 2013 Dec 24. No abstract available.

41.

Intrapatient homogeneity of BRAFV600E expression in melanoma.

Menzies AM, Lum T, Wilmott JS, Hyman J, Kefford RF, Thompson JF, O'Toole S, Long GV, Scolyer RA.

Am J Surg Pathol. 2014 Mar;38(3):377-82. doi: 10.1097/PAS.0000000000000136.

PMID:
24335665
42.

Oncogenic suppression of PHLPP1 in human melanoma.

Dong L, Jin L, Tseng HY, Wang CY, Wilmott JS, Yosufi B, Yan XG, Jiang CC, Scolyer RA, Zhang XD, Guo ST.

Oncogene. 2014 Sep 25;33(39):4756-66. doi: 10.1038/onc.2013.420. Epub 2013 Oct 14.

PMID:
24121273
43.

BAP1 expression in cutaneous melanoma: a pilot study.

Murali R, Wilmott JS, Jakrot V, Al-Ahmadie HA, Wiesner T, McCarthy SW, Thompson JF, Scolyer RA.

Pathology. 2013 Oct;45(6):606-9. doi: 10.1097/PAT.0b013e3283653818. No abstract available.

PMID:
24018818
44.

Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis.

Marzese DM, Scolyer RA, Huynh JL, Huang SK, Hirose H, Chong KK, Kiyohara E, Wang J, Kawas NP, Donovan NC, Hata K, Wilmott JS, Murali R, Buckland ME, Shivalingam B, Thompson JF, Morton DL, Kelly DF, Hoon DS.

Hum Mol Genet. 2014 Jan 1;23(1):226-38. doi: 10.1093/hmg/ddt420. Epub 2013 Sep 6.

45.

Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression.

Long GV, Wilmott JS, Haydu LE, Tembe V, Sharma R, Rizos H, Thompson JF, Howle J, Scolyer RA, Kefford RF.

Pigment Cell Melanoma Res. 2013 Jul;26(4):499-508. doi: 10.1111/pcmr.12098. Epub 2013 May 3.

PMID:
23557327
46.

PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma.

Ye Y, Jin L, Wilmott JS, Hu WL, Yosufi B, Thorne RF, Liu T, Rizos H, Yan XG, Dong L, Tay KH, Tseng HY, Guo ST, de Bock CE, Jiang CC, Wang CY, Wu M, Zhang LJ, Hersey P, Scolyer RA, Zhang XD.

Nat Commun. 2013;4:1508. doi: 10.1038/ncomms2489.

47.

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.

Wilmott JS, Menzies AM, Haydu LE, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA, Long GV.

Br J Cancer. 2013 Mar 5;108(4):924-31. doi: 10.1038/bjc.2013.29. Epub 2013 Feb 12.

48.

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma.

Wilmott JS, Scolyer RA, Long GV, Hersey P.

Oncoimmunology. 2012 Sep 1;1(6):997-999.

49.

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA.

Am J Surg Pathol. 2013 Jan;37(1):61-5. doi: 10.1097/PAS.0b013e31826485c0.

PMID:
23026937
50.

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, Lo RS, Kefford RF, Scolyer RA, Long GV.

Mol Cancer Ther. 2012 Dec;11(12):2704-8. doi: 10.1158/1535-7163.MCT-12-0530. Epub 2012 Sep 7.

Supplemental Content

Loading ...
Support Center